Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine…
The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are…
Read More...
Read More...